NCT07283640 2025-12-22A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaM.D. Anderson Cancer CenterPhase 1 Not yet recruiting20 enrolled